Abstract
This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.
Lingua originale | English |
---|---|
pagine (da-a) | 843-850 |
Numero di pagine | 8 |
Rivista | Annals of the Rheumatic Diseases |
Volume | 74 |
DOI | |
Stato di pubblicazione | Pubblicato - 2015 |
Pubblicato esternamente | Sì |
Keywords
- Adolescent
- Anti-TNF
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Certolizumab Pegol
- DMARDs (biologic)
- Disease Activity
- Double-Blind Method
- Drug Therapy, Combination
- Immunoglobulin Fab Fragments
- Immunosuppressive Agents
- Maintenance Chemotherapy
- Methotrexate
- Middle Aged
- Polyethylene Glycols
- Remission Induction
- Rheumatoid Arthritis
- Severity of Illness Index
- Treatment Outcome
- Young Adult